TreDia s.r.o.

At TreDia s.r.o. in Prague, clinical research focuses on the link between cardiovascular disease and metabolic disorders, especially type 2 diabetes, obesity, overweight, and related cardiovascular risk. The studies are designed to evaluate whether new treatment approaches can better protect heart health while also supporting metabolic control.

• Testing a new oral therapy for people with type 2 diabetes who are overweight or living with obesity, with a focus on reducing major heart-related events.
• Comparing advanced diabetes treatments in patients with high cardiovascular risk to see which option better lowers the chance of serious outcomes such as heart attack and stroke.

This research also reflects interest in broader metabolic health, including chronic kidney disease alongside cardiovascular diseases, helping assess how modern therapies may improve outcomes in people with complex long-term conditions.